March 18, 2020– A new report from a respected, independent congressional advisory panel sheds light on several of the key questions surrounding the 340B drug pricing program. In its March 2020 report to Congress, the Medicare Payment Advisory Commission (MedPAC) examined whether participation in the 340B program leads to higher drug spending for Medicare patients with five … [Read more...]
340B Is Serving the Underserved
April 10, 2019— For far too many patients in the U.S., access to needed health care is often out of reach. Millions of Americans – including those who live with disabilities, those with lower incomes, and members of racial and ethnic minority groups – struggle to get needed care. But hospitals participating in the 340B drug pricing program are helping counter that trend by … [Read more...]
Federal Court Blocks Medicare 340B Cuts
December 28, 2018— A federal court has found the Department of Health & Human Services (HHS) exceeded its authority by making deep cuts to Medicare Part B drug payments to many 340B hospitals. The decision marks a major victory for hospitals and their patients. Ruling on Dec. 27, the U.S. District Court for the District of Columbia issued a permanent injunction against … [Read more...]
Hits & Misses: 340B Commentary Gets Some Things Right But Misses on Others
November 28, 2018— In a recent commentary published in the Journal of the American Medical Association (JAMA), authors Peter Bach of Memorial Sloan Kettering Cancer Center and Rachel Sachs of Washington University in St. Louis call for an alternative financial mechanism for the 340B program, claiming the 340B program has resulted in market distortions and shifts in physician … [Read more...]
Busy times for 340B in Washington
November 19, 2018—The midterm elections were not the only source of Washington-related news in recent weeks with implications for the health care system. When it comes to 340B, several key events occurred in the days leading up to Election Day that might have longer-lasting implications for the program than the makeup of the 116th Congress. White House thinks globally on … [Read more...]
Congressional Leader Urges Medicare to Reverse 340B Hospital Cuts
October 19, 2018—Responding to a call for help from hospital CEOs in his home state and across the country, U.S. Senate Minority Leader Chuck Schumer (D-N.Y.) has urged Trump administration health officials to reverse a nearly 30 percent cut in Medicare Part B drug reimbursement to hospitals in the 340B drug pricing program. Speaking at United Memorial Medical Center (UMMC) … [Read more...]
Drug Prices Continue to Soar and the Public Notices
March 27, 2018—A trio of new reports out this past week indicates that the historic rise in prescription drug prices in the U.S. continues and the American public is concerned. First, a report by Axios found the prices of the top 20 drugs prescribed in the U.S. rose by more than 200 percent in the past 14 months. Based on an analysis by Pharmacy Benefits Consultants, Axios … [Read more...]